Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations

被引：10
作者：
Santa-Maria, Cesar A. [1 ,2 ]
O'Donnell, Maureen [2 ]
Nunes, Raquel [2 ]
Wright, Jean L. [1 ,2 ]
Stearns, Vered [1 ]
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
[2] Johns Hopkins Sibley Mem Hosp, Baltimore, MD USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2022年 / 20卷 / 07期
关键词：
NEOADJUVANT CHEMOTHERAPY; PEMBROLIZUMAB; CONTROVERSIES; CAPECITABINE; SURVIVAL; THERAPY; TRIAL;
D O I：
10.6004/jnccn.2022.7025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The KEYNOTE-522 study is a practice-changing phase III randomized study that demonstrated that the addition of pembrolizumab to polychemotherapy improves outcomes in patients with high-risk early-ficacious with unprecedented pathologic complete response (pCR) rates, and clinically meaningful improvements in event-free survival high-grade treatment-related toxicity. The backbone regimen deviated from common practice, including the addition of carboplatin, lack of dose dense anthracyclines, and adjuvant capecitabine for reoptimizing care using the best available evidence.
引用
收藏
页码：738 / 744
页数：7
相关论文
共 29 条
  • [1] Ademuyiwa FO, 2021, Cancer Res, V81
  • [2] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
    Alberro, J. A.
    Ballester, B.
    Deulofeu, P.
    Fabregas, R.
    Fraile, M.
    Gubern, J. M.
    Janer, J.
    Moral, A.
    de Pablo, J. L.
    Penalva, G.
    Puig, P.
    Ramos, M.
    Rojo, R.
    Santesteban, P.
    Serra, C.
    Sola, M.
    Solarnau, L.
    Solsona, J.
    Veloso, E.
    Vidal, S.
    Abe, O.
    Abe, R.
    Enomoto, K.
    Kikuchi, K.
    Koyama, H.
    Masuda, H.
    Nomura, Y.
    Ohashi, Y.
    Sakai, K.
    Sugimachi, K.
    Toi, M.
    Tominaga, T.
    Uchino, J.
    Yoshida, M.
    Coles, C. E.
    Haybittle, J. L.
    Moebus, V.
    Leonard, C. F.
    Calais, G.
    Garaud, P.
    Collett, V.
    Davies, C.
    Delmestri, A.
    Sayer, J.
    Harvey, V. J.
    Holdaway, I. M.
    Kay, R. G.
    Mason, B. H.
    Forbe, J. F.
    Franci, P. A.
    [J]. LANCET ONCOLOGY, 2018, 19 (01) : 27 - 39
  • [3] Amiri-Kordestani L, 2015, ONCOLOGY-NY, V29, P843
  • [4] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
    Citron, ML
    Berry, DA
    Cirrincione, C
    Hudis, C
    Winer, EP
    Gradishar, WJ
    Davidson, NE
    Martino, S
    Livingston, R
    Ingle, JN
    Perez, EA
    Carpenter, J
    Hurd, D
    Holland, JF
    Smith, BL
    Sartor, CI
    Leung, EH
    Abrams, J
    Schilsky, RL
    Muss, HB
    Norton, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1431 - 1439
  • [5] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    Cortazar, Patricia
    Zhang, Lijun
    Untch, Michael
    Mehta, Keyur
    Costantino, Joseph P.
    Wolmark, Norman
    Bonnefoi, Herve
    Cameron, David
    Gianni, Luca
    Valagussa, Pinuccia
    Swain, Sandra M.
    Prowell, Tatiana
    Loibl, Sibylle
    Wickerham, D. Lawrence
    Bogaerts, Jan
    Baselga, Jose
    Perou, Charles
    Blumenthal, Gideon
    Blohmer, Jens
    Mamounas, Eleftherios P.
    Bergh, Jonas
    Semiglazov, Vladimir
    Justice, Robert
    Eidtmann, Holger
    Paik, Soonmyung
    Piccart, Martine
    Sridhara, Rajeshwari
    Fasching, Peter A.
    Slaets, Leen
    Tang, Shenghui
    Gerber, Bernd
    Geyer, Charles E., Jr.
    Pazdur, Richard
    Ditsch, Nina
    Rastogi, Priya
    Eiermann, Wolfgang
    von Minckwitz, Gunter
    [J]. LANCET, 2014, 384 (9938) : 164 - 172
  • [6] NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.
    Geyer, Charles E.
    Loibl, Sibylle
    Rastogi, Priya
    Seiler, Sabine
    Costantino, Joseph P.
    Vijayvergia, Namrata
    Cortazar, Patricia
    Lucas, Peter C.
    Denkert, Carsten
    Mamounas, Eleftherios P.
    Jackisch, Christian
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
    Gianni, Luca
    Huang, Chiun-Sheng
    Egle, Daniel
    Bermejo, Begona
    Zamagni, Claudio
    Thill, Marc
    Anton, Antonio
    Zambelli, Stefania
    Bianchini, Giampaolo
    Russo, Stefania
    Ciruelos, Eva
    Greil, Richrad
    Semiglazov, Vladimir
    Colleoni, Marco
    Kelly, Catherine
    Mariani, Gabriella
    Del Mastro, Lucia
    Maffeis, Ilaria
    Valagussa, Pinuccia
    Viale, Giuseppe
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [8] Landmark trials in the medical oncology management of early stage breast cancer
    Hensing, Whitney
    Santa-Maria, Cesar A.
    Peterson, Lindsay L.
    Sheng, Jennifer Y.
    [J]. SEMINARS IN ONCOLOGY, 2020, 47 (05) : 278 - 292
  • [9] FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
    Howie, Lynn J.
    Scher, Nancy S.
    Amiri-Kordestani, Laleh
    Zhang, Lijun
    King-Kallimanis, Bellinda L.
    Choudhry, Yasmin
    Schroeder, Jason
    Goldberg, Kirsten B.
    Kluetz, Paul G.
    Ibrahim, Amna
    Sridhara, Rajeshwari
    Blumenthal, Gideon M.
    Pazdur, Richard
    Beaver, Julia A.
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (10) : 2949 - 2955
  • [10] Loibl S, 2021, ANN ONCOL, V32
123